StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCNFree Report) in a research note issued to investors on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 1.5%

Shares of NASDAQ LPCN opened at $3.28 on Friday. Lipocine has a twelve month low of $2.75 and a twelve month high of $11.79. The stock’s 50 day moving average price is $3.24 and its 200-day moving average price is $4.13. The company has a market capitalization of $17.55 million, a PE ratio of -4.32 and a beta of 1.52.

Lipocine (NASDAQ:LPCNGet Free Report) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC increased its stake in Lipocine Inc. (NASDAQ:LPCNFree Report) by 6.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

(Get Free Report)

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Featured Stories

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.